Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Apr;101(4):e149-52.
doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11.

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Annemiek Broijl  1 , Marie-José Kersten  2 , Wendimagegn Ghidey Alemayehu  3 , Mark-David Levin  4 , Okke de Weerdt  5 , Edo Vellenga  6 , Ellen Meijer  7 , Shulamit Wittebol  8 , Bea C Tanis  9 , Petra B Cornelisse  3 , Marian Stevens-Kroef  10 , Gerard M J Bos  11 , Pierre W Wijermans  12 , Henk Lokhorst  7 , Pieter Sonneveld  13
Affiliations
Clinical Trial

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Annemiek Broijl et al. Haematologica. 2016 Apr.
No abstract available

Keywords: VRD; escalated dose; first relapse; multiple myeloma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram HOVON 86. The treatment data is summarized by the flow diagram. It shows the number and proportion of patients in a specific treatment cycle, and the number of off protocol patients along with the reason for going out of protocol treatment. The diagram is generated for all included patients in both phases together.
Figure 2.
Figure 2.
Kaplan-Meier survival curves among patients with multiple myeloma. (A) Progression-Free Survival; (B) Overall Survival; (C) Duration of response; (D) Time to next treatment; (E) Progression-Free Survival from start of maintenance; (F) Overall Survival from start of maintenance.
See this image and copyright information in PMC

References

    1. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007;12(6):664–689. - PubMed
    1. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165–172. - PubMed
    1. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348(26):2609–2617. - PubMed
    1. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895–903. - PubMed
    1. Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol. 2008;141(6):814–819. - PubMed

MeSH terms